Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results ...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December ...

Jaguar Health’s (JAGX) Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget ...